Jingjing Liu

Jingjing Liu

Auto-generated profile, based on publicly available information

Jingjing Liu

Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2025 in Science Advances
Verified
Journal Article
Open access
XYXiaodong Yu
Xiaodong Yu
CHChenyuan Huang
Chenyuan Huang
MEMartijn Evers
Martijn Evers
JLJingjing Liu
Jingjing Liu
HTHui Jun Ting
Hui Jun Ting
Jiong-Wei WangJiong-Wei Wang
Jiong-Wei Wang
Increasing evidence implicates ceramides in the pathogenesis of metabolic dysfunction-associated steatohepatitis (MASH). However, the therapeutic potential of liver-targeted ceramide lowering remains unclear. In this study, we demonstrate that elevated ceramide levels in MASH patients and mouse models are closely associated with the activation of hepatic de novo ceramide synthesis. The analysis of human hepatic single-nucleus RNA sequencing (snRNA-seq) data revealed predominant up-regulation of SPTLC2 , which encodes a subunit of the rate-limiting enzyme in the de novo ceramide synthesis pathway, in hepatocytes. By targeted inhibition of SPTLC2 with lipid nanoparticle–mediated siRNA delivery to hepatocytes, we reduced both hepatic and circulating ceramide levels. This intervention suppressed hepatic lipid uptake and lipogenesis, thereby alleviating MASH progression. Therapeutic efficacy was demonstrated in an 8-week methionine-choline–deficient diet-induced MASH model and validated in a 1-year choline-deficient high-fat diet–induced MASH model. Our findings highlight hepatocyte Sptlc2 as a promising therapeutic target for MASH.

11 February 2023 in ACS Nano
Verified
Journal Article
Closed access
JLJingjing Liu
Jingjing Liu
XYXiaodong Yu
Xiaodong Yu
HTHui Jun Ting
Hui Jun Ting
XWXiaoyuan Wang
Xiaoyuan Wang
SXShidang Xu
Shidang Xu
BLBin Liu
Bin Liu

5 February 2025 in Journal of Controlled Release
Verified
Journal Article
Closed access
LYLin Yu
Lin Yu
LGLulu Gao
Lulu Gao
BLBing Liang
Bing Liang
LZLu Zhang
Lu Zhang
MWMin Wu
Min Wu
JLJingjing Liu
Jingjing Liu

1 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
KLKe Li
Ke Li
SHSihan Hu
Sihan Hu
HLHanwen Li
Hanwen Li
WLWenzheng Lin
Wenzheng Lin
DZDuoyi Zhao
Duoyi Zhao
HCHao Chen
Hao Chen
Resident leptin-receptor-expressing (LepR+) cells senescence in the aged bone marrow impairs the regenerative capacity of osteo- and other lineages of cells. In this study, a LepR+ cell-targeting nitric oxide (NO) nanopump with in vivo self-controlled turn-on ability was constructed to rejuvenate the LepR+ cells in the aged bone marrow. The nanopump co-entrapped hydrophobic chemiluminescence substrate and NO donor into the matrix of amphiphilic polymer through a nanoprecipitation process. The chemiluminescence substrate in the NO nanopump automatically reacts with the accumulated H2O2 in the aged bone marrow and then directly transfers the chemical energy to the NO donor to induce in situ NO release. The NO produced in situ within the aged bone marrow triggered the regeneration of the osteoblastic and the other niches in vivo through activating the glycolysis signaling in the senescent LepR+ cells. Conclusively, the constructed NO nanopump is a promising tool to counter aging-induced bone marrow disorders.

23 January 2025 in ACS Biomaterials Science & Engineering
Verified
Journal Article
Closed access
LYLin Yu
Lin Yu
XQXueying Qin
Xueying Qin
BLBing Liang
Bing Liang
JLJingjing Liu
Jingjing Liu

13 June 2024 in Acta Biomaterialia
Verified
Journal Article
Closed access
XQXueying Qin
Xueying Qin
JLJingjing Liu
Jingjing Liu